Loading publications…
The last 5 uploaded publications
First-in-human results of terbium-161[ <sup>161</sup> Tb]Tb-PSMA-I&T radioligand treatment in patients with metastatic castration-resistant prostate cancer (VIOLET): A single-centre, single-arm, phase I/II study.
James Buteau, Louise Kostos, Price Jackson, Lachlan McIntosh, Ramin Alipour, Timothy Akhurst, Michal Eifer, Brittany Emmerson, Mohammad B. Haskali, Kerry Jewell, Raghava Kashyap, Grace Kong, Declan G. Murphy, Aravind S. Ravi Kumar, Javad Saghebi, Shahneen Sandhu, Ben Tran, Jing Xie, Arun Azad, Michael S. Hofman (2025). First-in-human results of terbium-161[ <sup>161</sup> Tb]Tb-PSMA-I&T radioligand treatment in patients with metastatic castration-resistant prostate cancer (VIOLET): A single-centre, single-arm, phase I/II study.. , 43(16_suppl), DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.5010.
Article62 days agoLutetium-177–PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial
Edmond M. Kwan, Sarah W.S. Ng, Sofie H. Tolmeijer, Louise Emmett, Shahneen Sandhu, James Buteau, Amir Iravani, Anthony M. Joshua, Roslyn J. Francis, Vinod Vijay Subhash, Sze-Ting Lee, Andrew M. Scott, Andrew Martin, Martin R. Stockler, Gráinne Donnellan, Matti Annala, Cameron Herberts, Ian D. Davis, Michael S. Hofman, Arun Azad, Alexander W. Wyatt (2025). Lutetium-177–PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial. , DOI: https://doi.org/10.1038/s41591-025-03704-9.
Article62 days agoClonal hematopoiesis (CH) in participants with metastatic castration-resistant prostate cancer (mCRPC) receiving <sup>177</sup> Lu-PSMA-617 or cabazitaxel: An exploratory post-hoc analysis of a randomized phase II trial (TheraP; ANZUP 1603).
Aslı D. Munzur, Cameron Herberts, Edmond M. Kwan, Louise Emmett, Shahneen Sandhu, James Buteau, Amir Iravani, Anthony M. Joshua, Roslyn J. Francis, Sze Ting Lee, Andrew M. Scott, Andrew Martin, Martin R. Stockler, Alison Yan Zhang, Scott Williams, Jack V. W. Bacon, Arun Azad, Ian D. Davis, Michael S. Hofman, Alexander W. Wyatt (2025). Clonal hematopoiesis (CH) in participants with metastatic castration-resistant prostate cancer (mCRPC) receiving <sup>177</sup> Lu-PSMA-617 or cabazitaxel: An exploratory post-hoc analysis of a randomized phase II trial (TheraP; ANZUP 1603).. , 43(16_suppl), DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.5020.
Article62 days agoSafety and Efficacy of 20 Cycles of [<sup>177</sup>Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
Kerry Jewell, James Buteau, Elizabeth Medhurst, Edmond M. Kwan, Shahneen Sandhu, Arun Azad, Michael S. Hofman (2025). Safety and Efficacy of 20 Cycles of [<sup>177</sup>Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. , 66(6), DOI: https://doi.org/10.2967/jnumed.124.269447.
Article62 days agoTherapy-Related Myeloid Neoplasms After [<sup>177</sup>Lu]Lu-PSMA Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A Case Series
Michal Eifer, Duncan E. K. Sutherland, Isaac Goncalves, James Buteau, Lewis Au, Arun Azad, Louise Emmett, Grace Kong, Louise Kostos, Aravind S. Ravi Kumar, Edmond M. Kwan, Elizabeth Medhurst, Shahneen Sandhu, Ben Tran, Alexander W. Wyatt, Michael S. Hofman (2025). Therapy-Related Myeloid Neoplasms After [<sup>177</sup>Lu]Lu-PSMA Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A Case Series. , DOI: https://doi.org/10.2967/jnumed.124.268640.
Article62 days ago